Coherus BioSciences Inc. (NASDAQ:CHRS)’s share price was up 1.9% during mid-day trading on Tuesday . The stock traded as high as $26.48 and last traded at $26.31, with a volume of 154,671 shares changing hands. The stock had previously closed at $25.82.

Several equities research analysts have recently weighed in on CHRS shares. Zacks Investment Research lowered Coherus BioSciences from a “hold” rating to a “sell” rating in a research report on Thursday, May 12th. Citigroup Inc. started coverage on Coherus BioSciences in a research report on Wednesday, July 27th. They set a “buy” rating and a $36.00 target price on the stock. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $32.60.

The firm has a 50 day moving average of $20.08 and a 200 day moving average of $18.39. The firm’s market cap is $1.07 billion.

Coherus BioSciences (NASDAQ:CHRS) last released its earnings results on Monday, May 9th. The company reported ($1.67) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.42) by $0.25. On average, equities research analysts forecast that Coherus BioSciences Inc. will post ($5.76) earnings per share for the current fiscal year.

In other Coherus BioSciences news, insider Peter K. Watler sold 3,991 shares of the company’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $26.13, for a total transaction of $104,284.83. Following the completion of the sale, the insider now directly owns 3,991 shares in the company, valued at $104,284.83. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Alan C. Herman sold 4,250 shares of the company’s stock in a transaction dated Friday, July 1st. The stock was sold at an average price of $16.89, for a total value of $71,782.50. Following the sale, the insider now owns 198,115 shares of the company’s stock, valued at $3,346,162.35. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Coherus BioSciences stock. Jennison Associates LLC boosted its stake in Coherus BioSciences Inc. (NASDAQ:CHRS) by 3.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 367,021 shares of the company’s stock after buying an additional 11,023 shares during the period. Jennison Associates LLC owned approximately 0.94% of Coherus BioSciences worth $8,427,000 as of its most recent SEC filing.

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is focused on the global biosimilar market. The Company operates through developing and commercializing biosimilar products segment. Its business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta), in late clinical-stage, and bevacizumab (Avastin), in preclinical-stage; Immunology (Anti-TNF) biosimilar candidates, etanercept (Enbrel) and adalimumab (Humira), which are both in late clinical-stage; Ophthalmology biosimilar candidate ranibizumab (Lucentis) in preclinical stage, and Multiple sclerosis small molecule therapeutic candidate, CHS-131 (formerly INT-131), in Phase II proof-of-concept trial.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.